title: One-hour plasma glucose identifies insulin resistance and beta-cell dysfunction in individuals with normal glucose tolerance: cross-sectional data from the Relationship between Insulin Sensitivity and Cardiovascular Risk (RISC) study.
abstract: OBJECTIVE
  Some individuals with normal glucose tolerance (NGT) exhibit a 1-h excursion of plasma glucose during oral glucose tolerance testing as high as that of individuals with impaired glucose tolerance (IGT). The aim of this study was to characterize their metabolic phenotype.
  
  
  METHODS
  A total of 1,205 healthy volunteers (aged 29-61 years) underwent assessment of 1) oral glucose tolerance and 2) insulin sensitivity (standardized euglycemic-hyperinsulinemic clamp), as part of the Relationship between Insulin Sensitivity and Cardiovascular Risk (RISC) study.
  
  
  RESULTS
  One-hour plasma glucose correlated better than 2-h plasma glucose with total insulin secretion (r = 0.43), beta-cell glucose sensitivity (r = -0.46), and beta-cell rate sensitivity (r = -0.18). Receiver operating characteristic analysis identified 8.95 mmol/l as the best cutoff value for prediction of IGT from 1-h plasma glucose (sensitivity 77% and specificity 80%). Participants with NGT with 1-h plasma glucose >8.95 mmol/l had larger waist circumference, higher BMI, lower insulin sensitivity, higher fasting glucose, and higher insulin secretion than their counterparts with 1-h plasma glucose <or=8.95 mmol/l (P < 0.001 for all comparisons). Moreover, they exhibited lower beta-cell glucose sensitivity (P < 0.001), beta-cell rate sensitivity (P < 0.001), and potentiation factor (P = 0.026). When compared with conventionally defined IGT, they were not different in waist circumference and BMI, hepatic insulin extraction, beta-cell glucose sensitivity, beta-cell rate sensitivity, and potentiation factor but did have greater insulin sensitivity along with reduced basal (P = 0.001) and total insulin secretion (P = 0.002).
  
  
  CONCLUSIONS
  Higher values of 1-h plasma glucose may identify an intermediate condition between NGT and IGT characterized by greater insulin resistance, reduced beta-cell glucose sensitivity, and reduced beta-cell rate sensitivity.
authors.affiliation: Bambino Gesù Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy. melaniamanco@tiscali.it
authors.forename: Melania
authors.initials: M
authors.lastname: Manco
authors.forename: Simona
authors.initials: S
authors.lastname: Panunzi
authors.forename: David P
authors.initials: DP
authors.lastname: Macfarlane
authors.forename: Alain
authors.initials: A
authors.lastname: Golay
authors.forename: Olle
authors.initials: O
authors.lastname: Melander
authors.forename: Thomas
authors.initials: T
authors.lastname: Konrad
authors.forename: John R
authors.initials: JR
authors.lastname: Petrie
authors.forename: Geltrude
authors.initials: G
authors.lastname: Mingrone
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000032:analysis* / Q000378:metabolism*; D003430:Cross-Sectional Studies; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D007333:Insulin Resistance / Q000502:physiology*; D050417:Insulin-Secreting Cells / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies
chemical_list: D001786:Blood Glucose
references.citation: J Clin Endocrinol Metab. 2005 Feb;90(2):747-54
references.pmid: 15522932
references.citation: Diabetes Care. 2006 May;29(5):1130-9
references.pmid: 16644654
references.citation: Am J Physiol Endocrinol Metab. 2002 Dec;283(6):E1159-66
references.pmid: 12388151
references.citation: Diabetes Care. 2003 Mar;26(3):688-96
references.pmid: 12610023
references.citation: Diabetes Care. 2009 Sep;32(9):1583-8
references.pmid: 19587364
references.citation: Diabetes Care. 2007 Jun;30(6):1544-8
references.pmid: 17384342
references.citation: Diabetologia. 2004 Jan;47(1):31-9
references.pmid: 14666364
references.citation: J Clin Endocrinol Metab. 2005 Jan;90(1):493-500
references.pmid: 15483086
references.citation: Diabetes Care. 2003 Jan;26 Suppl 1:S5-20
references.pmid: 12502614
references.citation: Diabetes Care. 2007 Mar;30(3):753-9
references.pmid: 17327355
references.citation: Diabetes Care. 2008 Aug;31(8):1650-5
references.pmid: 18487478
references.citation: Diabetes Care. 1999 Feb;22(2):233-40
references.pmid: 10333939
references.citation: Diabetes Care. 2010 Mar;33(3):557-61
references.pmid: 20007945
references.citation: Diabetes. 2002 Feb;51 Suppl 1:S221-6
references.pmid: 11815483
references.citation: Diabet Med. 2002 Sep;19(9):708-23
references.pmid: 12207806
references.citation: Diabetes Obes Metab. 2008 Nov;10 Suppl 4:77-87
references.pmid: 18834435
references.citation: N Engl J Med. 2002 Feb 7;346(6):393-403
references.pmid: 11832527
references.citation: Diabetes Care. 2009 Mar;32(3):456-61
references.pmid: 19106382
references.citation: Diabetologia. 2004 Mar;47(3):566-570
references.pmid: 14968294
references.citation: J Clin Invest. 1997 Sep 1;100(5):1166-73
references.pmid: 9303923
references.citation: Diabetologia. 1996 Dec;39(12):1577-83
references.pmid: 8960845
references.citation: J Clin Endocrinol Metab. 2006 Mar;91(3):813-9
references.pmid: 16352690